Loading clinical trials...
Loading clinical trials...
To Assess the Long-term Efficacy and Safety of Combined Therapy With Ezefeno Tab. in Patients With Dyslipidemia Who do Not Achieve Adequate Control of Non-HDL-C Levels Even With Moderate-intensity Monotherapy
The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are: * major adverse cardiovascular events within 48 months of the trial duration * microvascular events within 48 months of the trial duration
A prospective, randomized, open-label, parallel, multicenter, active-drug-controlled clinical trial to assess the long-term efficacy and safety of Combined Therapy with Ezefeno Tab. in patients with dyslipidemia who do not achieve adequate control of Non-HDL-C levels even with Moderate-intensity monotherapy.
Age
19 - No limit years
Sex
ALL
Healthy Volunteers
No
Korea University Anam Hospital
Seoul, South Korea
Start Date
March 1, 2024
Primary Completion Date
February 1, 2027
Completion Date
February 1, 2027
Last Updated
August 27, 2024
3,958
ESTIMATED participants
Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin
DRUG
Dose escalation of moderate-intensity statin
DRUG
Lead Sponsor
Korea University Anam Hospital
NCT07321678
NCT06568471
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06322056